Literature DB >> 1706177

A prospective study of acute central retinal artery obstruction. The incidence of secondary ocular neovascularization.

J S Duker1, A Sivalingam, G C Brown, R Reber.   

Abstract

We conducted a prospective study to determine the incidence of ocular neo-vascularization following acute central retinal artery obstruction. Only patients initially evaluated within 7 days of visual loss were eligible. Any patient with pre-existing ocular neovascularization or clinical evidence of the ocular ischemic syndrome noted at the initial evaluation was excluded. During the 18-month study, 33 consecutive patients were enrolled. Six patients subsequently developed neovascularization of the iris, an incidence of 18.2%. In these six patients, neovascularization of the iris appeared as early as 12 days to as late as 15 weeks following the artery obstructions. Five of the six patients (15.2% of the total) later developed neovascular glaucoma. Another patient in this series developed neovascularization of the optic disc without neovascularization of the iris, an incidence of 3.0%. Only two of the seven patients with ocular neovascularization had ipsilateral hemodynamically significant carotid artery disease as determined by noninvasive carotid artery testing. This study confirms results of previous retrospective studies that the incidence of ocular neovascularization after central retinal artery obstruction is higher than commonly thought. It also shows that, in the majority of cases, carotid artery disease is not responsible for the neovascularization seen after central retinal artery obstruction.

Entities:  

Mesh:

Year:  1991        PMID: 1706177     DOI: 10.1001/archopht.1991.01080030041034

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  20 in total

1.  Neovascular glaucoma after branch retinal artery occlusion.

Authors:  Kaoruko Yamamoto; Akitaka Tsujikawa; Masanori Hangai; Masashi Fujihara; Takuji Iwawaki; Yasuo Kurimoto
Journal:  Jpn J Ophthalmol       Date:  2005 Sep-Oct       Impact factor: 2.447

2.  Multicenter study of the European Assessment Group for Lysis in the Eye (EAGLE) for the treatment of central retinal artery occlusion: design issues and implications. EAGLE Study report no. 1 : EAGLE Study report no. 1.

Authors:  N Feltgen; A Neubauer; B Jurklies; C Schmoor; D Schmidt; J Wanke; H Maier-Lenz; M Schumacher
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-12-22       Impact factor: 3.117

Review 3.  [Occlusion of the retinal artery].

Authors:  N Feltgen; D Schmidt; L Hansen
Journal:  Ophthalmologe       Date:  2003-08       Impact factor: 1.059

4.  Werner's syndrome.

Authors:  G Rosenthal; V Assa; T Monos; B Biedner; T Lifshitz; H Zirkin; E Finkelstein; A Lazarov
Journal:  Br J Ophthalmol       Date:  1996-06       Impact factor: 4.638

5.  A case of traumatic retinal avulsion at the optic nerve head.

Authors:  P Andreou; M P Clarke; P Feeney
Journal:  Br J Ophthalmol       Date:  1996-06       Impact factor: 4.638

6.  [Guidelines from the DOG, RG and BVA: retinal artery occlusion : November 2016 status].

Authors: 
Journal:  Ophthalmologe       Date:  2017-02       Impact factor: 1.059

7.  Combined central retinal artery-central vein obstruction.

Authors:  G C Brown; J S Duker; R Lehman; R C Eagle
Journal:  Int Ophthalmol       Date:  1993-02       Impact factor: 2.031

8.  Prognosis of central retinal artery occlusion: local intraarterial fibrinolysis versus conservative treatment.

Authors:  Dieter P Schmidt; Jürgen Schulte-Mönting; Martin Schumacher
Journal:  AJNR Am J Neuroradiol       Date:  2002-09       Impact factor: 3.825

9.  Intra-arterial fibrinolytic therapy in central retinal artery occlusion.

Authors:  M Schumacher; D Schmidt; A K Wakhloo
Journal:  Neuroradiology       Date:  1993       Impact factor: 2.804

10.  Retinal artery occlusion: associated systemic and ophthalmic abnormalities.

Authors:  Sohan Singh Hayreh; Patricia A Podhajsky; M Bridget Zimmerman
Journal:  Ophthalmology       Date:  2009-07-03       Impact factor: 12.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.